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Abstract
Background: The novel Malawi polyomavirus (MWPyV) was initially detected in stool specimens from healthy
children and children with gastrointestinal symptoms, mostly diarrhea, indicating that MWPyV might play a role in
human gastroenteric diseases. Recently, MWPyV sequences were additionally identified in respiratory secretions
from both healthy and acutely ill children suggesting that MWPyV may have a tropism for different human tissues.
This study was designed to investigate the possible sites of latency/persistence for MWPyV in a cohort of healthy
Italian children.
Methods: Specimens (n° 500) of tonsils, adenoids, blood, urines and feces, from 200 healthy and
immunocompetent children (age range: 1–15 years) were tested for the amplification of the MWPyV LT antigen
sequence by quantitative real-time PCR. Samples (n° 80) of blood and urines from 40 age-matched children with
autoimmune diseases, were screened for comparison. Polyomaviruses JC/BK and Epstein-Barr Virus (EBV) were also
tested as markers of infection in all samples using the same molecular technique.
Results: In our series of healthy children, MWPyV was detected only in the lymphoid tissues showing a prevalence
of 6 % in tonsils and 1 % in adenoids, although with a low viral load. No JCPyV or BKPyV co-infection was found in
MWPyV positive samples, while EBV showed a similar percentage of both in tonsils and adenoids (38 and 37 %).
Conversely, no MWPyV DNA was detected in stool from babies with gastroenteric syndrome. With regards to
autoimmune children, neither MWPyV nor BKPyV were detected in blood, while JCPyV viremia was observed in
15 % (6/40) of children treated with Infliximab. Urinary BKPyV shedding was observed in 12.5 % (5/40) while JCPyV
in 100 % of the samples.
Conclusions: The detection of MWPyV sequences in tonsils and adenoids of healthy children suggests that
secondary lymphoid tissues can harbour MWPyV probably as transient sites of persistence rather than actual sites of
latency.
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Background
The family of human polyomaviruses (PyVs), a group of
small DNA viruses, has recently grown to include 13
members, raising the question of their potential role in
humans, with and without manifest diseases [1–4].
PyVs seem to be harmless in immunocompetent indi-
viduals, but they can cause diseases in immunocomprom-
ised patients. The etiological role in human diseases has
been established for 4 of the 13 human polyomaviruses,
including tumors without productive viral replication and
non-neoplastic productive viral infections.
The known human polyomaviruses BKPyV and JCPyV,
display potential tumorigenic characteristics, although
their role in human cancers remains controversial [5–7].
The only human PyV to have been recognized as potential
oncovirus is the recently discovered Merkel cell polyoma-
virus (MCPyV), which seems to be a causal factor in Mer-
kel cell carcinoma, an aggressive skin malignancy [8–11].
On the other hand, BKPyV, but also JCPyV, is associated
with polyomavirus nephropathy (PVAN) in renal trans-
plant recipients, and BKPyV is also associated with
hemorrhagic cystitis in bone marrow transplant patients,
kidney allograft dysfunction and potential graft loss [12–
15]. JCPyV is the etiological agent of progressive multi-
focal leukoencephalopathy (PML) [16, 17], while the Tri-
chodysplasia Spinulosa-associated polyomavirus (TSPyV)
is thought to be the etiological agent of trichodysplasia
spinulosa, also known as pylomatrix dysplasia, a rare skin
disease characterized by the development of follicular pap-
ules and keratin spines [18–20].
Nothing is known on the possible role in human diseases
of the newly discovered polyomaviruses WUPyV and
KIPyV, the Saint Louis polyomavirus (STLPyV), the Malawi
polyomavirus (MWPyV), the Human polyomavirus 12
(HPyV12) and the New Jersey polyomavirus (NJPyV),which
have been detected in different human biological samples
including naso-pharyngeal secretions [21–24], stool [25,
26], liver and vascular endothelial cells [4, 27]. However,
HPyVs have been proposed as candidate causative factors
in a number of diseases with unknown etiology. For
instance, the association between these novel polyoma-
viruses and the primary mucosal melanomas has recently
been investigated, albeit without significant results [28].
PyVs are ubiquitous viruses in the human population,
with no less than 20 %, and up to 90 %, of the adult popu-
lation carrying antibodies against these viruses, depending
on the PyV strains, the geographic area and on the demo-
graphic characteristics of the study cohorts [29–31].
For almost all the members of the PyVs family, the
route of intra-human transmission is still unknown.
However, strong evidence indicates that JCPyV and
BKPyV can establish latency in the genitourinary tract
[32, 33], since episodes of self-limiting asymptomatic re-
activation by intermittent urinary shedding or viremia
can occur during severely impaired immune surveillance
[34]. Nevertheless, other organ niches such as the
gastroenteric trait [35], the lymphoid tissues [36, 37] and
the central nervous system [38–41] have also been sug-
gested as potential sites of latency.
The secondary lymphoid tissue has been proposed as a
possible site of persistence for WUPyV, KIPyV and TSPyV
by some authors, [42–44]. Moreover, MWPyV and STLPyV
sequences were recently detected in 2 % of tonsillar swabs
from children with chronic tonsillar disease, raising the
question of how the lymphoid system may play a role in
human polyomavirus infection and persistence [45].
Among new Polyomaviruses, particular attention has
been dedicated, in Italy, to the Malawi polyomavirus since a
sero-epidemiological survey on a large sample of subjects
(from 1 to ≥ 80 years old), has documented the circulation
of this virus with a trend of frequency similar to that
reported for the human polyomaviruses JC and BK. Specif-
ically, MWPyV seroconversion was shown to occur early in
childhood, with 26.9 % of 1- to 2-year-old children testing
seropositive, although seropositivity peaked (68.2 %) in 3-
to 4-year-old children [46].
MWPyV was initially identified by shotgun pyrosequenc-
ing of DNA extracted from virus-like particles isolated
from a stool sample collected from a healthy child in
Malawi. MWPyV is an unenveloped icosahedral virion
containing a small, closed circular double-strand DNA
genome of 4927 bp. The complete DNA sequencing
showed a MWPyV genome structure typical of the Polyo-
maviridae family, divided into three regions: the regulatory
region, the early region and the late region. The early
region encodes the large T antigen (LTAg) and small T
antigen (STAg), while the late region is expressed after viral
replication and encodes the structural proteins of the
capsid VP1, VP2, VP3. The regulatory region contains the
origin of replication and the promoter genes for transcrip-
tion of the early and late regions [25].
Following, MWPyP was found in 2.3 % of fecal sam-
ples from patients with gastrointestinal diseases [25].
Subsequently, a novel highly divergent polyomavirus,
provisionally named MXPyV, was identified by deep se-
quencing from diarrheal stool samples in Mexico. The
whole-genome sequence of MXPyV was found to be
nearly identical to that of polyomaviruses MWPyV and
HPyV10, indicating that these three viruses are different
variants of the same species [47]. The detection of
MWPyV in stool of children with diarrhea, often without
known etiology, raised the hypothesis that MWPyV might
play a role in human gastroenteric diseases. It is also pos-
sible, however, that MWPyV has a tropism for other hu-
man tissues and is shed in stool as a mode of intra-human
transmission [48]. Conversely, Rockett et al. reported the
presence of MWPyV in respiratory secretions from
acutely ill patients and in babies (<18 months old) with
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mild upper respiratory symptoms [49]. Therefore, the
question of which virus excretion route drives human in-
fection has not, as yet, been fully resolved.
One of the key points that need to be explored is whether
MWPyV is a pathogen of humans, and if so what diseases
are associated with its infection, or rather an environmental
contaminant that transiently infects humans.
The present study was designed to investigate the site
of latency/persistence of MWPyV in healthy children.
Tonsil, adenoid, blood, urine and stool specimens from
age-matched Italian healthy and immunocompetent chil-
dren and from children with autoimmune disorders,
were screened for this purpose.
JCPyV and BKPyV, which are known to be present with
a high number of excreted virions in the urine and feces
of immunocompromised subjects [33, 35] and EBV con-




The demographic and clinical characteristics of 240 Italian
Caucasian children (200 immunocompetent (healthy) chil-
dren and 40 autoimmune children) of both sexes, aged 1
to 15 years and referred to the Pediatric Department of
the Children’s Hospital “Burlo Garofolo” in Trieste, Italy,
are detailed in Table 1.
Among the healthy children, group 1 consisted of 59
children aged 1 to 5 years old, and 41 children aged 6 to
15 years old (mean age of group 1: 5.4 years). These sub-
jects had undergone adeno-tonsillar surgery for hyper-
trophy of adenoids, defined as adenoids occupying over
80 % of the choanal space, and tonsils graded three (30/
100) or four (70/100), according to Brodsky’s classification
[50]. Four-hundred matched biological samples, including
blood, urine, tonsil and adenoid tissues, were collected
from these children.
Group 2, consisted of 100 healthy babies (mean age:
1.9 years; age range: 0–4 years old) affected by acute gastro-
intestinal pain and diarrhea. By the routine microbiological
analysis, ten percent of these children tested positive for
Enterovirus (10/100), 20 % for Norovirus (20/100), but all
samples resulted negative for other gastrointestinal viruses
including Rotavirus, Adenovirus, and Astrovirus.
The 40 autoimmune children (mean age: 8.5 years) in-
cluded 11 aged 1 to 5 years old, and 29 aged 6–15 years
old. These children were affected by inflammatory diseases
including Crohn’s disease (13/40), Ulcerative Rectocolitis
(7/40) and Juvenile Rheumatoid Arthritis (20/40). Twenty
of them had been treated with biological drug monotherapy
(Infliximab) because they were refractory to standard
pharmacological treatment, but were clinically well at the
time of sample collection (blood and urine).
Sample processing and DNA extraction
Upon arrival in the laboratory, all specimens were proc-
essed for DNA automated extraction. Twenty mg of fresh
tissue from tonsils and adenoids were diced into small
pieces, suspended for digestion in a mixture composed by
400 μL of easyMAG lysis buffer (bioMérieux, France) and
40 μL of proteinase K (200 μg/mL), and incubated at 56 °
C overnight. Stool specimens were dissolved in sterile
water, vortexed and clarified by centrifugation at 6000 g
for 10 min (min), and the supernatant recovered for ex-
traction. Total available urines were collected in a 50 mL
tube, centrifuged at 4500 g for 20 min and the pellet
suspended in sterile water. Whole EDTA blood (100 μL)
was diluted in easyMAG lysis buffer (900 μL) at room
temperature for 10 min before extraction.
DNA isolation was performed using the NucliSensea-
syMAG platform (bioMérieux, France), according to the
manufacturer’s protocol. DNA was eluted to a final
volume of 50 μL and stored at −80 °C until analysis.
Table 1 Main demographic and clinical characteristics of
children cohorts
Healthy subjects No. 200
Group 1 No. 100
Age in years, mean 5.4
Age categories, number (percentage)
1–5 y 59 (59 %)
6–15 y 41 (41 %)
Female, number (percentage) 43 (43 %)
Diagnosis, number (percentage)
Tonsils/ Adenoids hypertrophy 100 (100 %)
Group 2a No. 100
Age in years, mean 1.9
Age categories, number (percentage)
0–4 y 100 (100 %)
Female, number (percentage) 70 (70 %)
Diagnosis, number (percentage)
Enterovirus 10 (10 %)
Norovirus 20 (20 %)
Autoimmune children No. 40
Age in years, mean 8.5
Age categories, number (percentage)
1–5 y 11 (27.5 %)
6–15 y 29 (72.5 %)
Female, number (percentage) 23 (57.5 %)
Diagnosis, number (percentage)
Crohn Disease 13 (32.5 %)
Juvenile Rheumatoid Arthritis (JRA) 20 (50.0 %)
Ulcerative Rectocolitis 7 (17.5 %)
aGastrointestinal disorder children
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Virological molecular detection
Quantitative real-time PCR (qPCR) assay was performed,
using TaqMan chemistry, to detect Malawi polyomavirus,
employing the AB PRISM 7500 Sequence Detection System
(Applied Biosystem, Milan, Italy). The specific primer pairs
were designed to detect the viral large T protein as previ-
ously described [25]. Serial 10-fold dilutions ranging from
109 to100 copies of a positive control plasmid (plasmid K-
p31, Addgene, USA) were performed to generate standard
curves. Briefly, the total 25 μL PCR mixture was composed
by 5 μL of extracted nucleic acid, 1 X universal TaqMan
real-time PCR master mix (Applied Biosystem), 12.5 pmol
of each primer and 4 pmol of the probe. The cycling condi-
tions were: 50 °C for 2 min, 95 °C for 10 min and 45 cycles
of 95 °C for 15 s followed by 60 °C for 1 min. A negative
control (containing water instead of DNA templates) and
one dilution of the plasmid as positive control were added
to each run. Based on the standard curve, the MWPyV
assay demonstrated a reliable detection limit of approxi-
mately five copies per reaction, yielded a linear regression
R2 value of 0.99, and was 93 % efficient.
Multiplex TaqMan qPCR was also performed on the
same samples to measure the viral loads of JCPyV and
BKPyV and to simultaneously amplify the reference hu-
man cellular β-globin gene in order to determine the cell
equivalents present in each sample and then to calculate
the proportion of infected cells (Euro-RT Polyoma Panel
kit; Eurospital Spa, Trieste, Italy). In addition, in lymph-
oid organs, human Epstein-Barr Virus (EBV), used as
reference lymphotropic virus, was assayed by specific
qPCR with TaqMan chemistry, using commercially avail-
able kits (Nanogen, Turin, Italy) according to manufac-
turer’s recommendations [51].
Finally, enteroviral-pathogens detection was performed
using a commercially available kit for Enterovirus (Elite
MGB Kit, Elitech Group, Puteaux, France), and by a
qualitative EIA test (enzyme immunoassay) (Ridascreen,
R-Biopharm, Darmstadt, Germany) for Norovirus, Adeno-
virus, Astrovirus and Rotavirus, following the supplier’s
recommendations.
Statistical analysis
The statistical analysis was performed using IBM SPSS
Statistics 20. Fisher Exact Test was used to compare the
frequencies of discrete variables. A P value ≤ 0.05 was
considered as the threshold of statistical significance.
Results
Human polyomaviruses detection
In this series of children, the overall prevalence of
MWPyV was 2.9 % (7/240). The infection was detected
only in the healthy/immunocompetent cohort (mean
age 6.8 years) where it reached a prevalence of 3.5 %
(7/200). No difference according to gender was ob-
served (p > 0.05) in these series.
With regards to the distribution of MWPyV infection,
considering all types of biological samples, as shown in
Table 2 the infection could only be detected in the lymph-
oid tissues of healthy children, and more precisely in tonsils
(6 %) and in adenoids (1 %). Infections were characterized
by low replication rates, typically ranging from 5 to 10 viral
copies/reaction. The proportion of infected cells, expressed
as the number of viral copies in the cells (% of infected
cells: from 0.05 to 1.0) and calculated on the basis of the
copies of β-globin (range: 3 × 103 to 1 × 104copies/reaction)
assuming that one copy of the viral genome infects one cell,
was constantly low. No JCPyV or BKPyV co-infection was
found in MWPyV positive samples, while the EBV lympho-
tropic reference showed a similar percentage of infection
both in tonsils and adenoids (38 and 37 % respectively).
Table 2 Prevalence of Malawi and JC/BK polyomavirus and EBV infections in biological samples from healthy and autoimmune
children
Samples Polyomavirus No. (%) Ref. virus No. (%)
Total No. MWPyV JCPyV BKPyV EBV
Healthy children
No. 200 Tonsil 100 6 (6 %) 0 0 38 (38 %)
Adenoid 100 1 (1 %) 0 0 37 (37 %)
Blood 100 0 0 0 12 (12 %)
Urine 100 0 0 0 –
Stoola 100 0 0 0 –
Total No. 500 7 (1.4 %) 0 0 –
Autoimmune children
No. 40 Blood 40 0 6 (15 %) 0 2 (5 %)
Urine 40 0 40 (100 %) 5 (12.5 %) –
Total No. 80 0 46 (57.5 %) 5 (6.25 %) –
a30 with acute gastrointestinal symptoms with a diagnosis of Enterovirus 10/30 and Norovirus 20/30 infections
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No MWPyV DNA was detected in stool specimens
from babies with gastroenteric syndrome with or with-
out diarrhea.
With regards to autoimmune children, neither MWPyV
nor BKPyV genomic sequences were detected in blood,
while JCPyV viremia was observed in 15 % (6/40) of the
samples (geometric mean viral load of 3.9 × 103 copies/
mL) recovered from children in therapy with Infliximab.
The lymphotropic EBV was also present in 5 % (2/40) of
the blood samples. Urinary BKPyV shedding was observed
in 12.5 % (5/40) (geometric mean viral load of 3.7 × 103
copies/mL) of the children, while JCPyV shedding was de-
tected in 100 % of the urine samples (geometric mean
viral load of 2.5 × 106copies/mL).
Discussion and conclusions
Several studies have reported the widespread distribu-
tion of MWPyV in different areas of the world, including
Africa, USA, Asia, Australia and South America [25, 45,
48, 49, 52]. A recent MWPyV seroprevalence survey on
the Italian general population has documented, for the
first time, the circulation of this polyomavirus also in
this geographic region [46].
The detection of MWPyV sequences in stool and re-
spiratory samples from healthy children in different geo-
graphical areas, suggests that the establishment of the
primary infection is likely to have taken place at an early
age, and that the gastrointestinal and/or respiratory tracts
may be sites of viral persistence. However, the relationship
of MWPyV with immunity is poorly understood, and this
can be explained by the absence of a recognizable clinical
condition and of a definitive identification of the human
tissues where it latently persists.
In the present study, based on the natural history of
other human polyomaviruses, tonsil and adenoid biopsies
and blood and urine specimens were screened in healthy
and autoimmune children, to investigate possible sites of
MWPyV persistence.
The results from this series, show an overall frequency
of MWPyV infection of 2.9 % which increases slightly to
3.5 %, when only the cohort of healthy children is con-
sidered. The discrepancy between the virus detection
rate and the high seroprevalence rate (from 26.9 % to
around 52 %) found in Italian healthy children of similar
age [46], suggests that MWPyV may infect a host niche
that has not yet been properly identified.
The association of MWPyV with gastroenteric symp-
toms (e.g., diarrhea) has suggested a possible role for this
virus in intestinal disorders, either acting alone or in
synergy with enteric pathogens [25, 53]. For this reason,
we tested stool specimens from healthy babies with diar-
rhea, 30 % of whom had a diagnosis of Entero- and Nor-
ovirus infections, but yielded no positive results. This
contrast in data may be due to the small number of
samples we analyzed (n°100) compared to the published
St. Louis series (n°514), and to the low prevalence rate of
infection (2.3 %) registered in that study [25]. In
addition, the frequency and duration of MWPyV stool
shedding after infection/reactivation has not, as yet, been
established with certainty, and this may have led to an
underestimation of infection in St. Louis study.
The results from this study seem to be in line with those
from a recent investigation by Rockett et al. in which
MWPyV was associated with upper respiratory infection
symptoms in >33 % of sole detection episodes, and only
rarely with gastrointestinal symptoms [49]. Moreover, in a
previous Australian study by the same author, MWPyV
viremia and viruria were not observed in either the healthy
or the autoimmune group, indicating that there was no sys-
temic involvement of peripheral lymphocytes [53]. Malawi
DNA is more likely to be detectable in blood during the
primary infection rather than during reactivation, the latter
being an event that depends on the specific biological
features of the virus, on local stimuli in infected tissues and
on the level of immunosuppression of the host [54].
The present study shows that MWPyV can infect lymph-
oid cells from healthy children, although at a lower rate
(7 %) than lymphotropic EBV (37.5 %) and WUPyV
(34.9 %) [43], thereby supporting the hypothesis of the tran-
sient nature of these tissues as sites of infection. These data
appear to be in contrast with those by Peng et al. [45],
which highlighted the role of tonsils as sites of persistence
also for MWPyV, despite the low rate of detection (2 %)
and the likelihood oral-pharyngeal contamination during
swab sampling of the mucosal surfaces of palatine tonsils.
Although previous studies have shown that different
polyomavirus strains can coexist in the same organ of
the same host, there is no evidence of BKPyV, JCPyV or
EBV co-infection in these tissues [55–57].
The association between diminished immunity and re-
activation is less clear for this novel human polyomavi-
rus. In our study, MWPyV was undetectable in the urine
and in the blood of autoimmune children, while, in
agreement with other published data, urinary shedding
of BKPyV and JCPyV was confirmed. Moreover, JCPyV
reactivation or subclinical infection was detected in the
blood of 6 children treated with biological drug, con-
firming the risk of developing PML as a result of long-
term of monoclonal therapy [58–60].
In conclusion, in this series of healthy immunocompe-
tent Italian children, no trace of MWPyV infection was
found in biological samples indicated by previous studies
as possible vehicles of intra-human transmission. Con-
versely, our data demonstrated that the secondary lymph-
oid tissues can actually harbour MWPyV. However, only
very few cells proved to be infected suggesting that these
tissues are unlikely to be the preferred site of latency, at
least in this series of children.
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Nevertheless, the high MWPyV seroprevalence found in
young children from this geographic area, and the in vitro
ability of MWPyV to bind to cellular tumor suppressor
factors and to promote chronic infection [52], seem to
support the hypothesis that infection/reactivation and
transmission of MWPyV may have clinical consequences
only in severely immunocompromised hosts. This obser-
vation warrants further investigations in organ transplant
recipients and AIDS and cancer patients.
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